ENTITY CLASS
Neuroactive research peptides
Semax, Selank, and DSIP research organized around the limits of human evidence and route-specific claims.
CONNECTED RECORDS
Neuroactive research peptides: evidence by entity.
Peptide analogHuman evidence 2/5
Semax
Semax has some human research, but the evidence is too limited and geographically concentrated to support broad cognitive-enhancement or neuroprotection claims.
Open evidence recordPeptide analogHuman evidence 2/5
Selank
Selank's human evidence is small and geographically concentrated. It is not a U.S.-approved anxiety treatment and should not be treated as equivalent to established therapies.
Open evidence recordNative peptideHuman evidence 1/5
DSIP
DSIP's therapeutic reputation rests on very small historical studies and uncertain physiology, not on a modern clinical development program.
Open evidence record